Clinical trials: TNF Alpha
Immune Function, Immunity
Effects of TM02® Supplementation on Immune Function in Children
This randomized, double-blind, placebo-controlled clinical study evaluated the effects of 12 weeks of TM02® supplementation on immune-related outcomes in generally healthy children aged 2 to 12 years.
- Trial name
- NCT07853573
- Testing
- TM02®
- Where
- Malaysia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ligno Biotech Sdn. Bhd.
Healthy
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety of human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection and Adalimumab when used…
- Trial name
- NCT02912247
- Testing
- human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.
GSK2800528 is being developed as a human anti-tumor necrosis factor (TNF) alpha monoclonal antibody (mAb) for the treatment of immune-inflammatory diseases.
- Trial name
- NCT01899755
- Testing
- GSK2800528, solution for injection, Adalimumab, solution for injection
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
This study will be conducted in healthy male or female subjects using a double-blind, randomized, placebo-controlled, single-dose design.
- Trial name
- NCT00950105
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Cancer, Nausea
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
The purpose of the study is verify the capability of a standardized Ginger (Zingiber officinale) extract to manage nausea in cancer patients receiving highly emetogenic treatments and standard anti-emetogenic therapy.
- Conditions
- Cancer, Nausea, Vomiting
- Trial name
- NCT01887314
- Testing
- Standardized Ginger extract
- Where
- 6 sites in Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Healthy
Study of ESBA105 Eye Drops in Healthy Subjects
Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
- Trial name
- NCT00671619
- Testing
- ESBA105
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ESBATech AG